Results 111 to 120 of about 7,490 (233)

MicroRNAs as new player in rheumatoid arthritis [PDF]

open access: yes, 2011
MicroRNAs (miRNAs) are small noncoding RNA molecules that negatively regulate gene expression at the post-transcriptional level. Currently, there are 939 mature human miRNA sequences listed in the Sanger updated miRNA registry.
Apparailly, F   +7 more
core   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo   +5 more
wiley   +1 more source

Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia

open access: yesBMC Infectious Diseases
Background X-linked agammaglobulinemia (XLA), also referred to as Bruton’s tyrosine kinase deficiency, is a rare genetic disorder that affects the immune system.
Bowen Dai   +15 more
doaj   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

open access: yes, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]

open access: yes, 2014
A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha   +4 more
core   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao   +8 more
wiley   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia

open access: yeseJHaem
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman   +2 more
doaj   +1 more source

Profound reduction of mature B cell numbers, reactivities and serum lg levels in mice which simultaneously carry the XID and CD40 deficiency gense [PDF]

open access: yes, 2017
It has been known for some time that single mutant nude or CD40T mice have apparently normal numbers of cells in the precursor compartments of bone marrow and the mature B cell compartments of the periphery.
Andersson, Jan   +8 more
core  

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy